Related Experiment Video

Updated: Jun 27, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy

Giovanni Martinelli1, Simona Soverini, Ilaria Iacobucci

  • 1Department of Hematology and Oncological Sciences, L e A Seràgnoli S Orsola-Malpighi Hospital, Bologna, Italy. giovanni.martinelli2@unibo.it

Nature Clinical Practice. Oncology
|December 19, 2008
PubMed

Insights

Optimizing dasatinib dosing for chronic myeloid leukemia (CML) patients resistant to imatinib shows intermittent therapy maintains effectiveness while reducing side effects, improving treatment outcomes.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Tyrosine kinase inhibitor (TKI) therapy has transformed chronic myeloid leukemia (CML) from a fatal illness to a manageable condition.
  • Current CML treatments include imatinib, dasatinib, and nilotinib, with ongoing research focused on optimizing strategies for efficacy and reduced toxicity.

Discussion:

  • A phase III study investigated dasatinib dose and schedule optimization in imatinib-resistant/intolerant CML patients.
  • Results indicate that intermittent targeted inhibition can maintain therapeutic efficacy.
  • This approach also demonstrated a reduction in treatment-related toxicity.

Key Insights:

  • Intermittent dasatinib dosing preserves therapeutic efficacy in CML patients.
  • Optimized dosing schedules can reduce adverse effects associated with TKI therapy.
  • This strategy offers a promising approach for managing CML and other malignancies.

Outlook:

  • Further research into optimized TKI dosing schedules is warranted.
  • Findings may inform the development of targeted therapies for various human cancers.
  • Personalized therapeutic strategies can improve patient outcomes in CML and beyond.

More Related Videos

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...